ELMD Share Price | Electromed, Inc. Stock Analysis & Recommendation

Q: How big is Electromed, Inc.?

Market Cap: As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Electromed, Inc. reported net sales of 61.43 million and a net profit of 7.16 million.Balance Sheet Snapshot: As of Jun 24, the company's shareholder's funds amounted to 44.55 million, while total assets were reported at 52.88 million.

Q: What does Electromed, Inc. do?

Overview:Electromed, Inc. develops, manufactures, and markets airway clearance products utilizing High Frequency Chest Wall Oscillation (HFCWO) therapy in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 16 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) Market-cap: USD 168.31 Million (Micro Cap)Key Metrics:P/E: 25.00 Dividend Yield: 0.00% Debt Equity: -0.35 Return on Equity: 16.30% Price to Book: 3.83 Contact Details:Address: 500 6th Ave NW, NEW PRAGUE MN: 56071-1134 Tel: ['1 952 7589299', '1 212 8369614'] Website: http://smartvest.com/

Q: Is Electromed, Inc. overvalued or undervalued?

As of 26 August 2025, the valuation grade for Electromed, Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 16.14, and a PEG ratio of 0.38, which suggests that the stock may not be undervalued despite its previous attractive rating.When compared to peers, Electromed's P/E ratio of 27.12 is higher than that of Clearpoint Neuro, Inc., which has a P/E of -13.98, indicating that Electromed is priced at a premium relative to some of its riskier counterparts. Additionally, the EV to EBITDA ratio for Electromed is more favorable than the average of its peers, which are generally in the risky category. Although specific return data is not available, Electromed's performance should be analyzed in the context of broader market trends, such as the S&P 500, to fully assess its valuation narrative.

Q: Is Electromed, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Electromed, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on the weekly but is mildly bearish on the monthly. Bollinger Bands are bullish on both weekly and monthly time frames, while moving averages indicate a mildly bearish trend on the daily. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory shows no trend on the weekly but is mildly bullish monthly. In terms of performance, Electromed has outperformed the S&P 500 over the past year with a return of 22.86% compared to the S&P 500's 17.14%, and significantly outperformed over the 3-year and 5-year periods as well. However, it has underperformed year-to-date with a return of -15.43% versus the S&P 500's 12.22%. Overall, the mixed indicators suggest a cautious outlook.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

49.58 k

Shareholding (Dec 2025)

FII

4.69%

Held by 30 FIIs

DII

76.56%

Held by 19 DIIs

Promoter

0.00%

How big is Electromed, Inc.?

22-Jun-2025

As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million and reported net sales of 61.43 million with a net profit of 7.16 million over the last four quarters.

View full answer

What does Electromed, Inc. do?

22-Jun-2025

Electromed, Inc. develops and markets airway clearance products using High Frequency Chest Wall Oscillation therapy, with recent net sales of $16 million and a market cap of $168.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.

View full answer

Who are in the management team of Electromed, Inc.?

22-Jun-2025

As of March 2022, the management team of Electromed, Inc. includes Independent Chairman Mr. Stephen Craney, President and CEO Ms. Kathleen Skarvan, and several Independent Directors: Mr. Stan Erickson, Mr. Gregory Fluet, Ms. Lee Jones, Ms. Andrea Walsh, and Dr. George Winn. They oversee the company's strategic direction and governance.

View full answer

Is Electromed, Inc. overvalued or undervalued?

20-Sep-2025

As of August 26, 2025, Electromed, Inc. is fairly valued with a P/E ratio of 25 and an EV to EBITDA of 16.14, indicating it is priced at a premium compared to some peers, despite its previous attractive rating.

View full answer

Is Electromed, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Electromed, Inc. shows a neutral trend with mixed technical indicators, having outperformed the S&P 500 over the past year but underperformed year-to-date, suggesting a cautious outlook.

View full answer

Compare Electromed, Inc. with Similar Stocks

Apyx Medical Corp.Citius Pharmaceuticals, Inc.Cutera, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 197 Million (Micro Cap)

P/E

22.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.30

Return on Equity

20.11%

Price to Book

4.33

Revenue and Profits:

Net Sales:

19 Million

(Quarterly Results - Dec 2025)

Net Profit:

3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-22.22%

6 Months

-6.84%

1 Year

-5.56%

2 Years

34.72%

3 Years

130.27%

4 Years

79.77%

5 Years

106.38%

Electromed, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

15.76%

EBIT Growth (5y)

26.97%

EBIT to Interest (avg)

4.74

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

1.37

Tax Ratio

25.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.38%

ROCE (avg)

17.40%

ROE (avg)

9.49%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.33

EV to EBIT

15.67

EV to EBITDA

14.22

EV to Capital Employed

5.78

EV to Sales

2.66

PEG Ratio

0.58

Dividend Yield

ROCE (Latest)

36.91%

ROE (Latest)

20.11%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 24 Schemes (18.75%)

Foreign Institutions

Held by 30 Foreign Institutions (4.69%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 11.83% vs -2.87% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 33.33% vs -4.55% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.90",
          "val2": "16.90",
          "chgp": "11.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.90",
          "val2": "2.90",
          "chgp": "34.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.80",
          "val2": "2.10",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "191.60%",
          "val2": "158.10%",
          "chgp": "3.35%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 17.00% vs 13.72% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 44.23% vs 62.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "64.00",
          "val2": "54.70",
          "chgp": "17.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.00",
          "val2": "7.40",
          "chgp": "48.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.50",
          "val2": "5.20",
          "chgp": "44.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "154.30%",
          "val2": "120.30%",
          "chgp": "3.40%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

18.90

16.90

11.83%

Operating Profit (PBDIT) excl Other Income

3.90

2.90

34.48%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

2.80

2.10

33.33%

Operating Profit Margin (Excl OI)

191.60%

158.10%

3.35%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 11.83% vs -2.87% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 33.33% vs -4.55% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

64.00

54.70

17.00%

Operating Profit (PBDIT) excl Other Income

11.00

7.40

48.65%

Interest

0.00

Exceptional Items

-0.20

0.00

Consolidate Net Profit

7.50

5.20

44.23%

Operating Profit Margin (Excl OI)

154.30%

120.30%

3.40%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 17.00% vs 13.72% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 44.23% vs 62.50% in Jun 2024

All Annual Results

Company CV

About Electromed, Inc.

Electromed, Inc.

Pharmaceuticals & Biotechnology

Electromed, Inc. develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company's products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. As of June 30, 2016, the SmartVest System is available in two models: SV2100 and SQL. The SmartVest System consists of an inflatable therapy garment, a programmable air pulse generator and a single-hose, which delivers air pulses from the generator to the garment. The SmartVest SQL System is small, quiet and light, and offers generator programmability. The Company markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to healthcare providers, particularly those working in intensive care units. The Company sells its products to the home healthcare market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis and neuromuscular disease.

Company Coordinates

Company Details

500 6th Ave NW , NEW PRAGUE MN : 56071-1134

Tel: 1 952 75892991 212 8369614

http://smartvest.com/

Registrar Details